suloctidil and Pulmonary-Embolism

suloctidil has been researched along with Pulmonary-Embolism* in 1 studies

Trials

1 trial(s) available for suloctidil and Pulmonary-Embolism

Article	Year
Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.). Thrombosis and haemostasis, 1982, Feb-26, Volume: 47, Issue:1 A double blind cross over study with suloctidil (Sulocton, Continental Pharma) and placebo was carried out for 6 months in 31 patients with idiopathic recurrent vein thrombosis. They were previously unsuccessfully treated with vitamin K antagonists (VKA) (18 patients) or acetylsalicylic acid (ASA) (13 patients) combined or not the a fibrinolysis activator (theophylline nicotinate). Clinical features, ultrasonic venous flow and biological parameters were controlled monthly during the 6 month treatment. Relevant improvement of clinical, ultrasonic and biological parameters was only observed under suloctidil therapy: during placebo administration 12 patients developed new thrombotic events complicated in 2 by pulmonary embolism while none occurred under suloctidil therapy. Topics: Adult; Aged; Antigens; beta-Thromboglobulin; Blood Platelets; Cell Survival; Factor VIII; Female; Humans; Male; Middle Aged; Platelet Factor 4; Platelet Function Tests; Propanolamines; Pulmonary Embolism; Recurrence; Suloctidil; Thrombophlebitis; Ultrasonography; Vitamin K	1982

Article

Year

Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.).

Thrombosis and haemostasis, 1982, Feb-26, Volume: 47, Issue:1

A double blind cross over study with suloctidil (Sulocton, Continental Pharma) and placebo was carried out for 6 months in 31 patients with idiopathic recurrent vein thrombosis. They were previously unsuccessfully treated with vitamin K antagonists (VKA) (18 patients) or acetylsalicylic acid (ASA) (13 patients) combined or not the a fibrinolysis activator (theophylline nicotinate). Clinical features, ultrasonic venous flow and biological parameters were controlled monthly during the 6 month treatment. Relevant improvement of clinical, ultrasonic and biological parameters was only observed under suloctidil therapy: during placebo administration 12 patients developed new thrombotic events complicated in 2 by pulmonary embolism while none occurred under suloctidil therapy.

Topics: Adult; Aged; Antigens; beta-Thromboglobulin; Blood Platelets; Cell Survival; Factor VIII; Female; Humans; Male; Middle Aged; Platelet Factor 4; Platelet Function Tests; Propanolamines; Pulmonary Embolism; Recurrence; Suloctidil; Thrombophlebitis; Ultrasonography; Vitamin K

1982